Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at StockNews.com

StockNews.com upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a buy rating to a strong-buy rating in a report published on Tuesday.

Other equities analysts have also recently issued research reports about the stock. Truist Financial reissued a buy rating and set a $1,200.00 target price (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 2nd. Morgan Stanley lowered their price objective on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an overweight rating on the stock in a research note on Thursday, July 11th. Argus upped their target price on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a buy rating in a research report on Tuesday, June 25th. Evercore ISI started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They set an outperform rating and a $1,150.00 price target on the stock. Finally, TD Cowen boosted their price objective on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a buy rating in a research note on Tuesday, July 23rd. One investment analyst has rated the stock with a sell rating, three have given a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of Moderate Buy and a consensus price target of $1,109.70.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $1,164.46 on Tuesday. Regeneron Pharmaceuticals has a 12-month low of $769.19 and a 12-month high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The firm has a market capitalization of $128.31 billion, a price-to-earnings ratio of 34.40, a price-to-earnings-growth ratio of 3.86 and a beta of 0.12. The business has a 50 day simple moving average of $1,121.84 and a 200 day simple moving average of $1,024.82.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The company had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm’s quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $8.79 EPS. On average, equities research analysts anticipate that Regeneron Pharmaceuticals will post 37.8 EPS for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the sale, the director now owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The disclosure for this sale can be found here. Insiders have sold a total of 10,026 shares of company stock valued at $11,498,705 over the last ninety days. Corporate insiders own 7.48% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 1.0% during the first quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock worth $8,595,268,000 after acquiring an additional 91,956 shares in the last quarter. Capital World Investors raised its stake in shares of Regeneron Pharmaceuticals by 0.5% during the 4th quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock worth $4,506,071,000 after purchasing an additional 23,146 shares in the last quarter. Capital International Investors lifted its holdings in shares of Regeneron Pharmaceuticals by 7.3% during the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after buying an additional 213,038 shares during the last quarter. Putnam Investments LLC grew its stake in shares of Regeneron Pharmaceuticals by 2.1% in the 4th quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock valued at $1,063,377,000 after buying an additional 24,329 shares in the last quarter. Finally, Norges Bank acquired a new position in Regeneron Pharmaceuticals in the fourth quarter worth approximately $932,571,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.